Oasis Pharmaceutical is structured around advancing novel treatments meaningfully to improve the health of patients with inflammatory, fibrotic, and metabolic disorders by targeting the G-protein coupled receptor (GPCR) Protease-activated Receptor 2 (PAR2). Anchored in use of pepducin chemistry to develop and commercialize novel therapeutics that uniquely target the critical intracellular domains of cell surface receptors, the firm's proprietary, cell-penetrating PAR2 pepducin technology is designed to advance a new generation of drugs to effectively treat inflammatory and fibrotic diseases. With facilities in Boston and Lexington MA., Oasis is currently developing a drug (PZ-235) - a protease-activated receptor-2 (PAR2) inhibitor. Development of the drug is an ongoing collaboration between Oasis and Tufts Medical Center in Boston, Massachusetts. Inhibiting PAR2 is thought to be a potential treatment for nonalcoholic steatohepatitis; blocking the actions of PAR2, PZ-235 is judged likely to prevent cirrhosis of the liver.
